ENDURA-KIT(ENDURACAINE)Post-Operative Pain Management

Current post-operative local anesthetic products have failed to gain mass adoption due to high toxicity, lack of effectiveness, and poor efficiency (high cost and poor results). Ventis Pharma has developed an effective new alternative to the current  medications that are available in this market segment. Initial studies with over 2500 patients, in off-label trials, have illustrated significant reductions in post-operative pain for long periods, with significantly decreased need for additional medications, including opioids. Patient and clinician acceptance has been excellent, with extremely limited adverse effects seen. Ventis Pharma’s new medication is called Enduracaine, which is preparing to complete US FDA IND tests and studies, as well as preparing for FDA clinical trials to further substantiate Enduracaine safety, efficacy and effectiveness. Because the product is a combination of currently approved USP products, its use prior to specific FDA approval of a new drug application is both safe and acceptable. TM Global